2. Membrane Transporter/Ion Channel Metabolic Enzyme/Protease Cytoskeleton Apoptosis
  3. Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis
  4. W-7

W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias.

For research use only. We do not sell to patients.

CAS No. : 65595-90-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of W-7:

W-7 Related Antibodies

Top Publications Citing Use of Products

    W-7 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Oct 29:S1097-2765(25)00822-6.  [Abstract]

    HEK293T cells expressing FLAG‑tagged RNF32 were treated with PMA and IO for 90 min, then immunoprecipitated (IP) with an anti‑RNF32 antibody in the presence or absence of the indicated CaM inhibitors W-7 hydrochloride (25-100 μM) or Calmidazolium. Whole cell extracts (WCEs) were immunoprecipitated with anti-FLAG resin. Immunocomplexes and WCEs were analyzed by immunoblotting. The results showed that the CaM inhibitors W-7 hydrochloride and Calmidazolium reduced the binding of RNF32 to the IKK complex in cells treated with PMA and IO.

    W-7 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Oct 29:S1097-2765(25)00822-6.  [Abstract]

    Immunofluorescence staining of endogenous RNF32 in U2OS cells stimulated with 10 ng/ml phorbol-12-myristate-13-acetate (PMA) and 950 nM ionomycin (IO) for 90 minutes with or without the CaM inhibitor W‑7 hydrochloride (25-100 μM). The results showed that the CaM inhibitors W‑7 hydrochloride greatly reduced the formation of RNF32 condensates. Scale bars indicate 10 µm.

    W-7 purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Dec 31;39(24):e71322.  [Abstract]

    Results of CCK-8 assays assessing the proliferation of OSCC cells (Cal-27, HN4) in the sgNC and sgORAI3 groups, as well as following treatment with inhibitors W-7 hydrochloride (10 μM) for calmodulin and CsA for calcineurin. Fold changes are relative to the optical density at a wavelength of 450 nm at time 0 h.

    W-7 purchased from MedChemExpress. Usage Cited in: FASEB J. 2025 Dec 31;39(24):e71322.  [Abstract]

    Representative images of scratch assays showing the migration of OSCC cells in the sgNC and sgORAI3 groups, as well as following treatment with W-7 hydrochloride (10 μM; 24-48 h) and CsA. Scale bar, 200 μm.

    W-7 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Aug 3:134478.  [Abstract]

    The relative expression levels of CaM and CN genes following inhibitor treatment at 48 h. The results showed that 10 μM W-7 hydrochloride (48 h) significantly downregulated CaM genes in both insects, while FK506 exhibited superior efficacy at 100 μM.

    W-7 purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Aug 3:134478.  [Abstract]

    The survival rate of G. molesta and C. chinensis after treatment with inhibitors and cyantraniliprole (CY). The results showed that injection or oral administration of W-7 hydrochloride (10 μM) or FK506 (100 μM) increased the sensitivity of both G. molesta and C. chinensis to cyantraniliprole (LC20), resulting in a notable rise in mortality rates, with the cyantraniliprole/W7 group showing the highest mortality.

    View All Calmodulin Isoform Specific Products:

    View All Isoforms
    CALM1 CALM2 CALM3

    View All Phosphodiesterase (PDE) Isoform Specific Products:

    View All Isoforms
    PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

    View All Myosin Isoform Specific Products:

    View All Isoforms
    MLCK

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    W-7 is a selective calmodulin antagonist. W-7 inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias[1][2][3][4][5][6].

    Cellular Effect
    Cell Line Type Value Description References
    Sf9 IC50
    50 μM
    Compound: W-7
    Inhibition of full-length recombinant human CamKII expressed in insect Sf9 cells incubated for 30 mins in presence of 5 uM CaM/[gamma32P]ATP by scintillation counting analysis
    Inhibition of full-length recombinant human CamKII expressed in insect Sf9 cells incubated for 30 mins in presence of 5 uM CaM/[gamma32P]ATP by scintillation counting analysis
    		[PMID: 27043269]
    In Vitro

    W-7 is distributed mainly in the cytoplasm, and inhibits proliferation of Chinese hamster ovary K1 (CHO-K1) cells. W-7 selectively blocks the phase of the cell cycle (G1/S boundary phase) in a manner. 25 μM W-7 arrests the growth of the cells at the G1/S boundary phase of the cell cycle[1].
    W-7 (100 μM) exhibits a similar extent of antagonism between the contractile responses to carbachol and KCl. The increase in myosin light chain (P-LC) phosphate content in response to 1-min stimulation with 10 μM carbachol is inhibited by W-7. W-7 antagonizes the smooth muscle contraction through the inhibition of the initial increase in the P-LC phosphorylation[2].
    Treatment with W-7 results in the dose-dependent inhibition of cell proliferation in various human multiple myeloma cell lines. W-7 induces G1 phase cell cycle arrest by downregulating cyclins and upregulating p21cip1. W-7 induces apoptosis via caspase activation; this occurred partly through the elevation of intracellular calcium levels and mitochondrial membrane potential depolarization and through inhibition of the STAT3 phosphorylation and subsequent downregulation of Mcl-1 protein[3].
    W-7 competitively inhibits Ca2+/calmodulin-dependent phosphodiesterase with a Ki value of 300 μM[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    W-7 Related Antibodies
    In Vivo

    W-7 (3 mg/kg; intraperitoneal injection; on 5 consecutive days per week; female BALB/c nu mice) treatment significantly reduces tumor growth in a murine MM model[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Female BALB/c nu mice (6-week-old) injected with RPMI 8226 cells[3]
    Dosage: 3 mg/kg
    Administration: Intraperitoneal injection; on 5 consecutive days per week
    Result: Significantly reduced tumor growth in a murine MM model.
    Molecular Weight

    340.87

    Formula

    C16H21ClN2O2S
    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    O=S(C1=C2C=CC=C(Cl)C2=CC=C1)(NCCCCCCN)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (293.37 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.9337 mL 14.6683 mL 29.3367 mL
    5 mM 0.5867 mL 2.9337 mL 5.8673 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (7.33 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (7.33 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.9337 mL 14.6683 mL 29.3367 mL 73.3417 mL
    5 mM 0.5867 mL 2.9337 mL 5.8673 mL 14.6683 mL
    10 mM 0.2934 mL 1.4668 mL 2.9337 mL 7.3342 mL
    15 mM 0.1956 mL 0.9779 mL 1.9558 mL 4.8894 mL
    20 mM 0.1467 mL 0.7334 mL 1.4668 mL 3.6671 mL
    25 mM 0.1173 mL 0.5867 mL 1.1735 mL 2.9337 mL
    30 mM 0.0978 mL 0.4889 mL 0.9779 mL 2.4447 mL
    40 mM 0.0733 mL 0.3667 mL 0.7334 mL 1.8335 mL
    50 mM 0.0587 mL 0.2934 mL 0.5867 mL 1.4668 mL
    60 mM 0.0489 mL 0.2445 mL 0.4889 mL 1.2224 mL
    80 mM 0.0367 mL 0.1834 mL 0.3667 mL 0.9168 mL
    100 mM 0.0293 mL 0.1467 mL 0.2934 mL 0.7334 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    W-7 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    W-765595-90-6W7W 7CalmodulinPotassium ChannelPhosphodiesterase (PDE)MyosinApoptosisCaMCalcium-Modulated ProteinKcsAvascular relaxingarrhythmiasInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    W-7
    Cat. No.:
    HY-130368
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.